Table 4.
Ten-year, Single Institution Experience for CA 19-9 in Periampullary Diseases
| Pre-treatment Serum CA 19-9 | |||
|---|---|---|---|
| N | Mean ± SD | Geom. Mean | |
| Ampullary adenocarcinoma | 26 | 309 ± 422 | 107.1 |
| Ampullary neuroendocrine | 3 | 23 ± 18 | 14.5 |
| Bile duct stricture | 8 | 32 ± 22 | 24.8 |
| Intraductal papillary mucinous neoplasm | 54 | 50 ± 181 | 15.0 |
| Mucinous cystic neoplasm | 27 | 31 ± 63 | 15.6 |
| Pancreatic acinar cell carcinoma | 3 | 8 ± 3 | 7.4 |
| Pancreatic adenocarcinoma | 324 | 12,917 ± 84,783 | 395.4 |
| Pancreatic adenosquamous carcinoma | 2 | 6,463 ± 8,869 | 1563.6 |
| Pancreatic neuroendocrine | 48 | 27 ± 43 | 12.0 |
| Pancreatitis | 37 | 43 ± 72 | 15.5 |
| Pseudocyst | 40 | 176 ± 1,026 | 9.2 |
| Serous cystadenoma | 19 | 19 ±12 | 15.3 |
| Simple cyst | 3 | 29 ± 28 | 20.6 |
| Solid-cystic papillary neoplasm | 6 | 12 ± 11 | 8.8 |
| Malignanta | 355 | 11,848 ± 81,062 | 340.9 |
| Benignb | 194 | 67 ± 476 | 13.0 |
| Pancreatic adenocarcinoma | 324 | 12,917 ± 84,783 | 395.4 |
| Pancreatitis/Pseudocyst | 77 | 112 ± 740 | 11.8 |
| Pancreatic adenocarcinomac | 321 | 13,035 ± 85,171 | 401.6 |
| IA + IB + IIA (localized disease) | 46 | 616 ± 1,187 | 142.0 |
| IIB + III + IV (locally advanced or metastatic disease) | 278 | 15,112 ± 91,877 | 477.9 |
| IA + IB + IIA + IIB (resectable) | 131 | 733 ± 2,215 | 165.3 |
| III + IV (unresectable) | 190 | 21,516 ± 110,006 | 740.6 |
| IPMN + MCN (potentially pre-malignant) | 81 | 43 ± 152 | 15.1 |
a
includes ampullary adenocarcinoma, pancreatic acinar cel carcinoma, pancreatic adenocarcinoma, and pancreatic adenosquamous carcinoma; excludes neuroendocrine
b
includes pancreatitis, pseudocyst, solid-cystic papillary neoplasm, intraductal papillary mucinous neoplasm (IPMN), serous cystadenoma, mucinous cystic neoplasm (MCN), simple cyst, bile duct stricture
c
excludes cases without stage information